5'-Deoxy-5'-[(2-hydrazinoethyl)methylamino]adenosine | 144224-28-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 5'-Deoxy-5'-[(2-hydrazinoethyl)methylamino]adenosine
• 英文别名: (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[2-hydrazinylethyl(methyl)amino]methyl]oxolane-3,4-diol
• CAS: 144224-28-2
• 化学式: C₁₃H₂₂N₈O₃
• 分子量: 338.37
• InChiKey: ATZTZWNADRKXQE-QYVSTXNMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  161
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT
  申请人：Pathologica LLC

  公开号：EP3228310A1

  公开（公告）日：2017-10-11

  The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.

  本发明提供了调节受试者体内骨化素活性以及治疗或预防与受试者体内骨化素活性增加有关的疾病的方法。
• COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3473247A1

  公开（公告）日：2019-04-24

  The present invention relates to an oral pharmaceutical composition, comprising methylglyoxal bis(guanylhydrazone) (MGBG) together with at least one oral pharmaceutically acceptable excipient, for use in the treatment or delaying the onset or development of multiple sclerosis when orally administered to a subject.

  本发明涉及一种口服药物组合物，包括甲基乙二醛双（鸟苷腙）（MGBG）和至少一种口服药物可接受赋形剂，用于口服给受试者治疗或延缓多发性硬化症的发作或发展。
• MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3831372A1

  公开（公告）日：2021-06-09

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。
• Methods and compositions for treatment of demyelinating diseases
  申请人：Pathologica LLC

  公开号：US10085955B2

  公开（公告）日：2018-10-02

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。
• Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
  申请人：Pathologica LLC

  公开号：US10292950B2

  公开（公告）日：2019-05-21

  Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

  本文公开了用于治疗炎症和/或疼痛等疾病的化合物、药物组合物和方法，其中包括施用治疗有效量的非类固醇、非阿片类化合物，该化合物具有胃肠道/肾脏/血小板疏松活性和较宽的安全边际，对两种形式的环氧化酶均无明显抑制作用。